Thomas K. Equels - 06 Mar 2026 Form 4 Insider Report for AIM ImmunoTech Inc. (AIM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
10 Mar 2026, 17:56:40 UTC
Prior SEC filing
13 Jun 2025
Next SEC filing
16 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Thomas K Equels

Key filing fact

Thomas K. Equels filed Form 4 for AIM ImmunoTech Inc. (AIM) on 10 Mar 2026.

Key facts

  • This page summarizes Thomas K. Equels's Form 4 filing for AIM ImmunoTech Inc. (AIM).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 10 Mar 2026, 17:56.

Change

  • Previous filing in this sequence was filed on 13 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001450324 Primary reporting owner

Equels Thomas K

Relationship
CEO & President
Address
2117 SOUTHWEST HIGHWAY 484, OCALA,
Signature
/s/ Thomas K Equels
Signature date
10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AIM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
38,922
Date
06 Mar 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AIM transaction Derivative

Series G Convertible Preferred Stock

Other

Transaction value
Shares
+25
Change %
Price
$25000.00*
Shares after
25
Date
06 Mar 2026
Ownership
Direct
Underlying class
Series G Convertible Preferred Stock
Underlying amount
25
Exercise price
$1000.00
Footnotes
F1, F2
AIM transaction Derivative

Class G Warrants

Other

Transaction value
Shares
+50,000
Change %
Price
$0.000000*
Shares after
50,000
Date
06 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$1.00
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each share has a stated value of $1,000 and is convertible into 1,000 shares of common stock and was issued as part of a subscription right issued in a rights offering.

Footnote F2

n/a - Preferred shares are perpetual.

Footnote F3

Each warrant is exercisable for one share of common stock at an exercise price of $1.00 per share and was issued as part of a subscription right issued in a rights offering.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .